The appeal stems from Pfizer’s challenge to the Madras High Court’s decision, which declined to assist in enforcing the US ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer has filed an appeal against a Madras High Court order that turned down its prayer to enforce Letters Rogatory to ...

The Supreme Court today, while hearing a plea by US pharmaceutical giant Pfizer, asked whether foreign courts and Western ...

The Supreme Court on Thursday opined that execution of Letters Rogatory - a request from a foreign court for judicial assistance - cannot come at the cost ...

Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the ...

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

Pfizer is also making strides in the weight management market. It now owns one of the more promising mid-stage assets in this ...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun Pharmaceutical (Group) Co. for an early-stage weight-loss drug. The agreement with ...

Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space.

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal. The U.S. drugmaker ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...